AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C

ÖVÜNÇ, KURDAŞ Ayşe Oya; Güzelbulut, Fatih; sezikli, mesut; YASAR, BÜLENT; AKKAN ÇETİNKAYA, ZÜLEYHA; Özkara, Selvinaz

AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C

Fatih GÜZELBULUT, (Sağlık Bakanlığı, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İstanbul, Türkiye)

ZÜLEYHA AKKAN ÇETİNKAYA, (Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Patoloji Kliniği, İstanbul, Türkiye)

Mesut SEZİKLİ, (Sağlık Bakanlığı, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İstanbul, Türkiye)

Bülent YAŞAR, (Sağlık Bakanlığı, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İstanbul, Türkiye)

Selvinaz ÖZKARA, (Sağlık Bakanlığı, Kocaeli Derince Eğitim ve Araştırma Hastanesi, Kocaeli, Türkiye)

KURDAŞ Ayşe Oya ÖVÜNÇ (Sağlık Bakanlığı, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İstanbul, Türkiye)

Turkish Journal of Gastroenterology

31 1

Yıl: 2011 Cilt: 22 Sayı: 3 Sayfa Aralığı: 279 - 285 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C

Öz:

Amaç: Bu çalışmadaki amacımız kronik hepatit C’li hastalarda belirgin fibrozis ve sirozun belirlenmesinde aspartat aminotransferaz- platelet oranı indeksi, Forns indeksi ve FIB-4’ün tanısal güvenilirliğini karaciğer biopsisi ile karşılaştırmalı olarak değerlendirmektir. Metod: 2004-2008 yılları arasında Gastroenteroloji Kliniği’ne başvuran kronik hepatit C’li hastaların bilgisayar kayıtları nı retrospektif olarak incelendi. Karaciğer biopsisi yapılmış ve aspartat aminotransferaz-platelet oranı indeksi, Forns indeksi ve FIB-4’ün hesaplanmasına olanak sağlayan laboratuvar test sonuçları olan hiç tedavi görmemiş kronik hepatit C’li hastalar çalı şmaya alındı. Fibrozisin derecesi METAVIR sistemine göre belirlendi. F2-4 belirgin fibrozis, F4 siroz olarak kabul edildi. Aspartat aminotransferaz-platelet oranı indeksi, Forns indeksi ve FIB-4 orijinal çalışmalar esas alınarak hesaplandı. Test sonuçları hafif fibrozis ile belirgin fibrozisi olan gruplar ve sirozu olmayanlarla sirozu olan gruplar arasında karşılaştırıldı. Bulgular: 150 kronik hepatit C’li hasta çalışmaya alındı. Belirgin fibrozisin belirlenmesinde Forns indeksi, aspartat aminotransferaz-platelet oranı indeksi ve FIB-4 için ROC eğrisi altında kalan alan sırası ile 0,795, 0,774 ve 0,764 idi. Sirozun belirlenmesinde Forns indeksi, aspartat aminotransferaz-platelet oranı indeksi ve FIB-4 için ROC eğrisi altında kalan alan sırası ile 0,879, 0,839 ve 0,874 idi. Sonuç: Forns indeksi, aspartat aminotransferaz-platelet oranı indeksi ve FIB-4, kronik hepatit C’li hastaların yarısında belirgin fibrozis ve sirozun belirlenmesinde güvenilir noninvaziv testlerdir. Hem belirgin fibrozis hem de sirozun belirlenmesinde Forns indeksi aspartat aminotransferaz-platelet oranı indeksine ve FIB-4’e göre hafif daha üstündür.

Anahtar Kelime:

Konular: Cerrahi

Kronik hepatit C’li hastalarda belirgin fibrozis ve sirozun belirlenmesinde AST-platelet oranı indeksi, Forns indeksi ve FIB-4’ün yeri

Öz:

Background/aims: The aim of this study was to evaluate the diagnostic accuracy of aspartate aminotransferase-platelet ratio index, the Forns index and FIB-4 for the assessment of hepatic fibrosis in chronic hepatitis C patients by comparison with liver biopsy. Methods: We retrospectively reviewed our computerized data of chronic hepatitis C patients who admitted to the Gastroenterology Clinic between 2004 and 2008. Treatment-naive chronic hepatitis C patients who had undergone liver biopsy and had laboratory test results allowing the calculation of aspartate aminotransferase-platelet ratio index, the Forns index and FIB-4 were included in this study. The degree of fibrosis was scored according to the METAVIR staging system. Significant fibrosis was defined as F2-4 and cirrhosis as F4. Aspartate aminotransferase-platelet ratio index, the Forns index and FIB-4 were calculated based on the original studies. Tests results were compared between groups F0-1 (no or mild fibrosis) versus F2-4 (significant fibrosis) and F0- 3 (no cirrhosis) versus F4 (cirrhosis). Results: One hundred and fifty patients with chronic hepatitis C were included in this study. The areas under the ROC curves of the Forns index, aspartate aminotransferase-platelet ratio index and FIB-4 to predict significant fibrosis were 0.795, 0.774 and 0.764, respectively. The area under the ROC curves of the Forns index, aspartate aminotransferase- platelet ratio index and FIB-4 to predict cirrhosis were 0.879, 0.839 and 0.874, respectively. Conclusions: The Forns index, aspartate aminotransferase-platelet ratio index and FIB-4 were accurate noninvasive blood tests to predict the presence or absence of significant fibrosis and cirrhosis in half of the chronic hepatitis C patients. The Forns index was slightly better than the aspartate aminotransferase-platelet ratio index and FIB-4 in the prediction of significant fibrosis and cirrhosis.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
2. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.
3. Silva RG Jr, Fakhouri R, Nascimento TV, et al. Aspartate aminotransferase-to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients. Braz J Infect Dis 2008; 12: 15-9.
4. Sebastiani G, Vario A, Guide M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15: 212-8.
5. Cheung RC, Currie S, Shen H, et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol 2008; 42: 827-34.
6. Smith JO, Sterling LK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 557-76.
7. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
8. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775-82.
9. Kawamoto M, Mizuguchi T, Katsuramaki T, et al. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006; 12: 4325-30.
10. Friedrich-Rust M, Ong MF, Herrmann E, et al. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007; 188: 758-64.
11. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49: 1017-44.
12. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
13. Lin CS, Chang CS, Yang SS, et al. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 2008; 47: 569-75.
14. Koda M, Matunaga Y, Kawakami M, et al. Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306.
15. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology 2007; 46: 32-6.
16. Sterling LK, Lissen E, Clumeck N, et al. for the APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
17. Imbert-Bismut F, Ratziu V, Pieroni L, et al.; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
18. Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81.
19. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
20. Bourliere M, Penaranda G, Ouzan D, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458-67.
21. Halfon P, Bacq Y, De Murret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402.
22. Thabut D, Simon M, Myers RP, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003; 37: 1220-1.
23. Adler M, Gulbis B, Moreno C, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008; 47: 762-3.
24. Butt AA, Tsevat J, Ahmad J, et al. Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection. Am J Med Sci 2007; 333: 271-5.
25. Giannini E, Botta F, Fasoli A, et al. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HCV infection on this histological damage. Dig Dis Sci 2001; 46: 524-9.

APA	Güzelbulut F, AKKAN ÇETİNKAYA Z, sezikli m, YASAR B, Özkara S, ÖVÜNÇ K (2011). AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. , 279 - 285.
Chicago	Güzelbulut Fatih,AKKAN ÇETİNKAYA ZÜLEYHA,sezikli mesut,YASAR BÜLENT,Özkara Selvinaz,ÖVÜNÇ KURDAŞ Ayşe Oya AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. (2011): 279 - 285.
MLA	Güzelbulut Fatih,AKKAN ÇETİNKAYA ZÜLEYHA,sezikli mesut,YASAR BÜLENT,Özkara Selvinaz,ÖVÜNÇ KURDAŞ Ayşe Oya AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. , 2011, ss.279 - 285.
AMA	Güzelbulut F,AKKAN ÇETİNKAYA Z,sezikli m,YASAR B,Özkara S,ÖVÜNÇ K AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. . 2011; 279 - 285.
Vancouver	Güzelbulut F,AKKAN ÇETİNKAYA Z,sezikli m,YASAR B,Özkara S,ÖVÜNÇ K AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. . 2011; 279 - 285.
IEEE	Güzelbulut F,AKKAN ÇETİNKAYA Z,sezikli m,YASAR B,Özkara S,ÖVÜNÇ K "AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C." , ss.279 - 285, 2011.
ISNAD	Güzelbulut, Fatih vd. "AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C". (2011), 279-285.

APA	Güzelbulut F, AKKAN ÇETİNKAYA Z, sezikli m, YASAR B, Özkara S, ÖVÜNÇ K (2011). AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turkish Journal of Gastroenterology, 22(3), 279 - 285.
Chicago	Güzelbulut Fatih,AKKAN ÇETİNKAYA ZÜLEYHA,sezikli mesut,YASAR BÜLENT,Özkara Selvinaz,ÖVÜNÇ KURDAŞ Ayşe Oya AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turkish Journal of Gastroenterology 22, no.3 (2011): 279 - 285.
MLA	Güzelbulut Fatih,AKKAN ÇETİNKAYA ZÜLEYHA,sezikli mesut,YASAR BÜLENT,Özkara Selvinaz,ÖVÜNÇ KURDAŞ Ayşe Oya AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turkish Journal of Gastroenterology, vol.22, no.3, 2011, ss.279 - 285.
AMA	Güzelbulut F,AKKAN ÇETİNKAYA Z,sezikli m,YASAR B,Özkara S,ÖVÜNÇ K AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turkish Journal of Gastroenterology. 2011; 22(3): 279 - 285.
Vancouver	Güzelbulut F,AKKAN ÇETİNKAYA Z,sezikli m,YASAR B,Özkara S,ÖVÜNÇ K AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turkish Journal of Gastroenterology. 2011; 22(3): 279 - 285.
IEEE	Güzelbulut F,AKKAN ÇETİNKAYA Z,sezikli m,YASAR B,Özkara S,ÖVÜNÇ K "AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C." Turkish Journal of Gastroenterology, 22, ss.279 - 285, 2011.
ISNAD	Güzelbulut, Fatih vd. "AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C". Turkish Journal of Gastroenterology 22/3 (2011), 279-285.